Hyun Ah Yoon
<div id="cit_full" class="meta">
<p class="j"> </p>
</div>
<div class="ab"> </div>
Michael Yee
Gregory D. Weston
<p>Dr. Weston’s research interests include the epidemiology, mechanisms of resistance, and therapy of multi-drug resistant gram-negative infections, particularly Carbapenem-Resistant Enterobateriaceae. He works with mathematical modeling techniques to predict which patients are at high risk of CRE bloodstream infections. He also organizes Montefiore’s participation in the CRACKLE II multicenter database of CRE infections.</p>
<p>Dr. Weston’s inpatient clinical work is on a service dedicated to infectious disease consultation in the intensive care and step down units of Weiler hospital. This includes brief daily rounds with each unit to identify needs for consultation and provide antibiotic stewardship guidance. He is a member of the Montefiore Antibiotic Stewardship Team and also sees patients in an Outpatient Parenteral Antibiotic Therapy clinic.</p>
<p>Dr. Weston is a graduate of Regis High School in New York. He received his undergraduate education summa cum laude from the College of the Holy Cross in Worcester, Massachusetts. He received a medical degree from the College of Physicians and Surgeons of Columbia University in New York. He completed Internal Medicine residency at the Emory University School of Medicine in Atlanta, Georgia. Dr. Weston joined Montefiore Medical Center and the Albert Einstein College of Medicine in 2013 for his fellowship in Infectious Diseases. During Fellowship he completed a Master’s of Science in Clinical Research degree in the Einstein Clinical Research Training Program. </p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28167547">Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.</a> Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN. <em>Antimicrobial Agents and Chemotherapy</em> 2017; 61: e02349-16</p>
<p>A multicenter study measuring appropriateness of carbapenem use. Weston G, Jacob JT, Ray S, Varkey J, Gaynes RP. Infection Control and Hospital Epidemiology 2013; 34: 1324-1326</p>
Louis M. Weiss
<p><em><span style="text-decoration: underline;">Toxoplasma gondii</span></em>, microsporidiosis, stage differentiation, polar tube structure and function</p>
<p><strong>Toxoplasmosis:</strong> <em>Toxoplasma gondii</em> is a ubiquitous Apicomplexan protozoan parasite that infects humans, mammals and birds. Despite recent progress in understanding the biology of the rapidly replicating form (tachyzoite), very little is known about the cyst form (bradyzoite). The bradyzoite stage plays a critical role in maintenance of latent infection, the relapse of infections and the development of chronic neurologcial disease. Our research is focused on the identification of cyst wall (bradyzoite) proteins and how they function. </p>
<p><strong>Microsporidiosis:</strong> The phylum Microspora consists of organisms collectively known as microsporidia, that are "emerging" human and veterinary pathogens. A microsporidian-specific organelle, the polar tube, is involved in invasion. While the description of the polar tube as a unique microsporidian structure occurred over 100 years ago, the biochemical components of this structure and the mechanism of its formation during invasion remain to be definitively determined. The laboratory is focused on projects invovling the: (1) characterization of the structure and composition of the polar tube and spore wall, and (2) the identificiation of therapeutic targets for the treatment of microsporidiosis. </p>
Treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.
Investigates the biology of Toxoplasma gondii and its ability to cause latent infections, with a focus on the composition and structure of the T. gondii tissue cyst.
<p>Mayoral J, Guevara RB, Rivera-Cuevas Y, Tu V, Tomita T, Romano JD, Gunther-Cummins L, Sidoli S, Coppens I, Carruthers VB, Weiss LM. Dense Granule Protein GRA64 interacts with host cell ESCRT proteins during <em>Toxoplasma gondii</em> infection.mBio. 2022 Jun 22:e0144222. doi: 10.1128/mbio.01442-22.</p>
<p>Tomita T, Mukhopadhyay D, Han B, Yakubu R, Tu V, Mayoral J, Sugi T, Ma Y, Saeij JPJ, Weiss LM. <em>Toxoplasma gondii</em> matrix antigen 1 is a secreted immunomodulatory effector. mBio. 2021 May 18;12(3):e00603-21. </p>
<p>Flores J, Takvorian PM, Weiss LM, Cali A, Gao N. Human microsporidian pathogen <em>Encephalitozoon intestinalis</em> impinges on enterocyte membrane trafficking and signaling. J Cell Sci. 2021 Feb 15:jcs.253757. doi: 10.1242/jcs.253757.</p>
<p>Mayoral J, Tomita T, Tu V, Aguilan JT, Sidoli S, Weiss LM. <em>Toxoplasma gondii</em> PPM3C, a secreted protein phosphatase, affects parasitophorous vacuole effector export. PLoS Pathog. 2020 Dec 28;16(12):e1008771. doi: 10.1371/journal.ppat.1008771. </p>
<p>Mayoral J, Shamamian P Jr, Weiss LM. In Vitro Characterization of protein effector export in the bradyzoite stage of Toxoplasma gondii. mBio. 2020 Mar 10;11(2). pii: e00046-20. doi: 10.1128/mBio.00046-20. PMID: 32156805</p>
<p><span lang="EN">Tu V, Tomita T, Sugi T, Mayoral J, Han B, Yakubu RR, Williams T, Horta A, Ma Y, Weiss LM. The <em>Toxoplasma gondii</em> cyst wall interactome. mBio. 2020 Feb 4;11(1). pii: e02699-19. doi: 10.1128/mBio.02699-19.PMID: 32019789</span></p>
<p>Tu V, Mayoral J, Yakubu RR, Tomita T, Sugi T, Han B, Williams T, Ma Y, Weiss LM.MAG2, a <em>Toxoplasma gondii</em> bradyzoite stage-specific cyst matrix protein. mSphere. 2020 Feb 19;5(1). pii: e00100-20. doi:10.1128/mSphere.00100-20.PMID: 32075884</p>
<p><span lang="EN">Han B, Ma Y, Tu V, Tomita T, Mayoral J, Williams T, Horta A, Huang H, Weiss LM Microsporidia interact with host cell mitochondria via voltage-dependent anion channels using sporoplasm Surface Protein 1. mBio. 2019 Aug 20;10(4). pii: e01944-19. doi: 10.1128/mBio.01944-19. PMID: 31431557</span> <span lang="EN">PMC6703431</span></p>
<p><span lang="EN">Takvorian PM, Han B, Cali A, Rice WJ, Gunther L, Macaluso F, Weiss LM. An ultrastructural study of the extruded polar tube of<em> Anncaliia algerae</em> (Microsporidia). J Eukaryot Microbiol. 2019 Jul 22. doi: 10.1111/jeu.12751. PMID: 31332877</span></p>
<p><span lang="EN">Tomita T, Wang H, Wu P, Weiss LM.Stage-specific and selective delivery of caged azidosugars into the intracellular parasite <em>Toxoplasma gondii</em> by using an esterase-ester pair technique. mSphere. 2019 May 29;4(3). pii: e00142-19. doi: 10.1128/mSphere.00142-19. PMID: 31142619</span></p>
<p>Tu V, Mayoral J, Sugi T, Tomita T, Han B, Ma YF, Weiss LM. Enrichment and proteomic characterization of the cyst wall from in vitro <em>Toxoplasma gondii</em> cysts. mBio. 2019 Apr 30;10(2). pii: e00469-19. doi: 10.1128/mBio.00469-19. PMID: 31040239</p>
<p>Sugi T, Tu V, Ma Y, Tomita T, Weiss LM. <em>Toxoplasma gondii</em> requires glycogen phosphorylase for balancing amylopectin storage and for efficient production of brain cysts. mBio. 2017 Aug 29;8(4). pii: e01289-17. doi: 10.1128/mBio.01289-17.PMID: 28851850 PMC5574715</p>
<p>Yakubu RR, Silmon de Monerri NC, Nieves E, Kim K, Weiss LM. Comparative Monomethylarginine proteomics suggests that protein arginine methyltransferase 1 (PRMT1) is a significant contributor to arginine monomethylation in <em>Toxoplasma gondii</em>. Mol Cell Proteomics. 2017 Apr;16(4):567-580. doi: 10.1074/mcp.M117.066951. Epub 2017 Jan 31.PMID: 28143887</p>
<p>Han B, Polonais V, Sugi T, Yakubu R, Takvorian PM, Cali A, Maier K, Long M, Levy M, Tanowitz HB, Pan G, Delbac F, Zhou Z, Weiss LM. The role of microsporidian polar tube protein 4 (PTP4) in host cell infection. PLoS Pathog. 2017 Apr 20;13(4):e1006341. doi: 10.1371/journal.ppat.1006341. eCollection 2017 Apr. PMID: 28426751</p>
<p>Sugi T, Ma YF, Tomita T, Murakoshi F, Eaton MS, Yakubu R, Han B, Tu V, Kato K, Kawazu S, Gupta N, Suvorova ES, White MW, Kim K, Weiss LM. Toxoplasma gondii cyclic AMP-dependent protein kinase subunit 3 is involved in the switch from tachyzoite to bradyzoite development. mBio. 2016 May 31;7(3). pii: e00755-16. doi: 10.1128/mBio.00755-16. PMID: 27247232 PMCID: PMC4895117</p>
<p>El Bissati K, Suvorova ES, Xiao H, Lucas O, Upadhya R, Yan Fen Ma YF, Hogue Angeletti R, White MW, Weiss LM, Kim K <em>Toxoplasma gondii</em> arginine methyltransferase 1 (PRMT1) regulates centrosome dynamics during tachyzoite cell division. mBio. 2016 Feb 2;7(1):e02094-15. doi: 10.1128/mBio.02094-15. PMID: 26838719 PMCID: PMC4742710</p>
<p>Silmon de Monerri NC, Yakubu RR, Chen AL, Bradley PJ, Nieves E, Weiss LM, Kim K. The Ubiquitin proteome of <em>Toxoplasma gondi</em>i reveals roles for protein ubiquitination in cell-cycle transitions. Cell Host Microbe. 2015 Nov 11;18(5):621-33. doi: 10.1016/j.chom.2015.10.014. PMID: 26567513</p>
<p>Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM.The <em>Toxoplasma gondii</em> cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. PLoS Pathog. 2013 Dec;9(12):e1003823. doi: 10.1371/journal.ppat.1003823. PMID:24385904</p>
<p>Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, Yarlett N. Continuous culture of <em>Cryptosporidium parvum</em> using hollow fiber technology. Int J Parasitol. 2015 Sep 2. pii: S0020-7519(15)00220-9. doi: 10.1016/j.ijpara.2015.07.006. PMID: 26341006</p>
<p>Ma Y, Weiss LM, Huang H. Inducible suicide vector systems for <em>Trypanosoma cruzi</em>. Microbes Infect. 2015 Jun;17(6):440-50. doi: 10.1016/j.micinf.2015.04.003. Epub 2015 Apr 18. PMID: 25899945</p>
<p>Nardelli SC, Che FY, Silmon de Monerri NC, Xiao H, Nieves E, Madrid-Aliste C, Angel SO, Sullivan WJ Jr, Angeletti RH, Kim K, Weiss LM. The Histone Code of <em>Toxoplasma gondii</em> Comprises Conserved and Unique Posttranslational Modifications. mBio. 2013 Dec 10;4(6). doi:pii: e00922-13. 10.1128/mBio.00922-13. PMID:24327343</p>
<p>Pombert JF,Selman M,Burki F,Bardell FT,Farinelli L,Solter LF,Whitman DW,Weiss LM, Corradi N, Keeling PJ. Gain and loss of multiple functionally related, horizontally transferred genes in the reduced genomes of two microsporidian parasites. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12638-43. Epub 2012 Jul 16. PMID:22802648</p>
<p>Ghosh K, Nieves E, Keeling P, CaliA, Weiss LM. A new vesicular compartment in <em>Encephalitozoon cuniculi</em>. Microbes Infect. 2012 Apr;14(4):324-8. PMID:22166342</p>
<p>Ghosh K, Nieves E, Keeling P, Pombert JF, CaliA, Weiss LM. A branching network of proteinaceous filaments within the parasitophorous vacuole of<em> Encephalitozoon cuniculi</em> and <em>Encephalitozoon hellem</em>. Infect Immun. 2011 Jan 10. PMID: 21220485</p>
<p>Bouzahzah B, Nagajyothi F, Ghosh K, Takvorian PM, CaliA, Tanowitz HB, Weiss LM. Interactions of <em>Encephalitozoon cuniculi</em> polar tube proteins. Infect Immun. 2010 Jun;78(6):2745-53. Epub 2010 Mar 22. PMID: 20308291</p>
<p>Alvarado JJ, Nemkal A, Sauder JM, Russell M, Akiyoshi DE, Shi W, Almo SC, Weiss LM. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol Biochem Parasitol. 2009 Aug 4. PMID: 19660503</p>
<p><strong>BOOKS</strong></p>
<p>Weiss LM and Kim K (eds.) <em>Toxoplasma gondii</em> the model Apicomplexan: Methods and Applications, Elsevier Press (Academic Press), 3rd edition, 2020.</p>
<p>Weiss LM and Reinke AW (eds.) Microsporidia: Current Advances in Biology, Springer, 2022.</p>
<p>Weiss LM and Becnel JJ (eds.) Microsporidia: Pathogens of Opportunity, Wiley-Blackwell, 2014.</p>
<p>Louis M. Weiss, MD, MPH, is Vice Chair, Academic Affairs and Research, Pathology, Co-Director, Einstein Global Health Center and Professor, Pathology and Medicine (Infectious Diseases) at Montefiore Einstein. His clinical expertise is in the treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.</p><p>After obtaining his Bachelor of Arts in biology and chemistry from Lehigh University in 1978, Dr. Weiss earned his Doctor of Medicine and Master of Public Health at Johns Hopkins University in 1982. Following this, Dr. Weiss completed his internship and residency in medicine at the University of Chicago in 1985 and an infectious diseases fellowship at Einstein Montefiore in 1989.</p><p>Dr. Weiss investigates the biology of <em>Toxoplasma gondii</em> and its ability to cause latent infections, with a focus on the composition and structure of the <em>T. gondii</em> tissue cyst. He also investigates the biology of infection due to the microsporidia, with a focus on the composition of the polar tube and how it functions during microsporidian invasion of a host cell. His research has been published in numerous peer-reviewed journals, articles, books and chapters, and he has presented this research both nationally and internationally. Dr. Weiss has been a reviewer for scientific journals including <em>mBIO</em>, the <em>Journal of Eukaryotic Microbiology</em>, the <em>American Journal of Tropical Medicine and Hygiene, PLOS Pathogens</em>, the <em>Journal of Infectious Diseases</em> and <em>Experimental Parasitology</em>, and is an editor for <em>mBIO</em> and <em>Microbes and Infection</em>.</p><p>Dr. Weiss is board certified in Internal Medicine and Infectious Diseases. He is a Fellow of the Infectious Diseases Society of America, the American College of Physicians and the American Academy of Microbiology of the American Society of Microbiology. In 2000, Dr. Weiss was inducted into the Leo M. Davidoff Society for his outstanding teaching of medical students.</p>
Victoria Vapnyar
Henry M. Ushay
Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure
Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children’s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics
<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children’s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children’s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>
Audrey M. Uong
Dr. Uong's clinical focus has been in pediatrics.
The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients.
<p>Audrey M. Uong, MD, is an Attending Physician, Division of Hospital Medicine at Children’s Hospital at Montefiore (CHAM) and an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2019, her clinical focus has been in pediatrics.</p><p>In 2008, Dr. Uong received her Bachelor of Arts in Asian Languages and Civilizations from Amherst College. Her studies continued at New York Medical College, where she received her Doctor of Medicine in 2014. Following this, Dr. Uong continued her studies at Albert Einstein Medical College and received her Master of Science in Clinical Research Methods in 2019. She began her postgraduate training in 2014 with a 3-year internship and residency at Cohen Children’s Medical Center. She then completed a fellowship in Pediatric Hospital Medicine at CHAM in 2019.</p><p>The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients. Her work has been published in numerous peer-reviewed journals and review articles, and has been presented nationally.</p><p>In 2019, Dr. Uong received the CHAM Research Day Oral Presentation Award, given to her from faculty judges for receiving top scores. Dr. Uong is board certified by the American Board of Pediatrics and is a member of numerous professional societies, including the American Academy of Pediatrics and the Academic Pediatric Association.</p>
Julian A. Torres Isasiga
<p>Dr. Torres completed his MD degree at Universidad del Valle (Cali, Colombia) in 2006. He then joined the International Center for Training and Medical Research (CIDEIM) in his home town, Cali, where he spent almost 3 years as a research assistant in the area of Gram negative Bacterial Resistance, where he published and presented his work in national and international journals and conferences.</p>
<p>After completing his Internal Medicine residency at Jacobi Medical Center in the Bronx, Dr. Torres completed his fellowship in Infectious Diseases at New York University (NYU). He then joined Englewood Hospital where he spent more than 2 years as an Infectious Disease consultant.</p>
<p>Dr. Torres joined Montefiore Medical Center/Albert Einstein College of Medicine in 2017 as an Assistant Professor. Since then, he has been providing PrEP, PEP, STI, HCV and HIV care to patients in the Bronx, as well as inpatient Infectious Disease consultation services at the hospital. He has an interest to expand HIV prevention projects in Colombia and is working closely with Corporacion de Lucha contra el SIDA in Cali.</p>
<p>Dr. Torres has been a member of the Infectious Disease Society of America since 2012.</p>
<p> </p>
<p> </p>
<p align="left"><strong><span style="font-family: Times New Roman; font-size: medium;">Selected Publications</span></strong><strong><span style="text-decoration: underline;"><span style="font-family: Times New Roman; font-size: medium;"><br /></span></span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Nori P, Szymczak W, Puius J, Sharma A, Cowman K, Fleischner Z, Bartash R, Chen V, Corpuz M, Gialanella P, Alpert P, Felsen U,<strong> Torres-Isasiga J</strong>, Guo Y. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;">Int J Antimicrob Agents. 56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179. Epub 2020 Sep 25.<strong> (2020)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mueses-Marín HF, Alvarado-Llano B, </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">Torres-Isasiga J</span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">, Camargo-Plazas P, Bolívar-Rocha MC, Galindo-Orrego X, Martínez-Cajas JL. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Scales to Assess Knowledge, Motivation, and Self-Efficacy for HIV PrEP in Colombian MSM: PrEP-COL Study. AIDS Research and Treatment, vol. 2021, Article ID 4789971, 11 pages </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2021)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Falsey AR, et al., </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">and the AstraZeneca AZD1222 Clinical Study Group (Julian A. Torres). </span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">. </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">N Engl J Med. </span><span lang="ES" style="font-size: 10.5pt; font-family: 'Segoe UI',sans-serif; color: #4d8055; background: white;"> </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">doi: 10.1056/NEJMoa21052902021. </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">(2021).</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas J, Alvarado-Llano B, Martínez-Buitrago E, <strong>Torres-Isasiga J</strong>, Arrivillaga M, Camargo P, Galindo-Orrego X, Mueses-Marín H. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/35067114/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">AC-2020-12-1420.R1 - HIV care providers' familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study.</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"> AIDS Care. doi: 10.1080/09540121.2022.2029813 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas JL, <strong>Torres J, </strong>Mueses HF, Camargo Plazas P, Arrivillaga M, Gomez SA, Galindo X, Martínez Buitrago E, Alvarado-Llano BE. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Applying Implementation Science Frameworks to Identify Factors that Influence the Intention of Healthcare Providers to Offer PrEP Care and Advocate for PrEP in HIV Clinics in Colombia: A Cross-Sectional Study. Implement Sci Commun. Mar 16; 3(1):31. doi.org/10.1186/s43058-022-00278-2 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Meyerowitz EA, Bernardo, RM, Collins-Ogle, MD, Mamber Czeresnia, J, Morales Matos, C, Mullis C, Root, H; <strong>Torres-Isasiga JA</strong>, Tsai, H; Zingman, B. Navigating HIV Screening Recommendations for People on PrEP and the Need to Update Testing Algorithms. </span><em><span lang="ES" style="color: black; mso-color-alt: windowtext;">Open Forum Infectious Diseases</span></em><span lang="ES" style="color: black; mso-color-alt: windowtext;">, ofac191. <a href="https://doi.org/10.1093/ofid/ofac191"><span style="color: black; mso-color-alt: windowtext; text-decoration: none; text-underline: none;">doi.org/10.1093/ofid/ofac191</span></a> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;">Arrivillaga M, Gómez SA, Mueses HF, Alvarado B, Martínez Buitrago E, Camargo-Plazas P, Hurtado LR, Bolívar MC, Galindo X, <strong>Torres J</strong>, Cajas-Martínez JL. Facilitadores y recomendaciones de proveedores de salud para la implementación de la Profilaxis Pre-Exposición en clínicas de VIH en Colombia. “Estudio PPrE-Colombia”. Rev Gerenc Polit Salud;21. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO; text-decoration: none; text-underline: none;">https://doi.org/10.11144/Javeriana.rgps21.frps</span></a></span><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;"> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: 0.5in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><!-- [if !supportLists]--><span lang="ES-CO" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: ES-CO;">·<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><!--[endif]--><span lang="ES-CO">Meyerowitz EA, Gendlina I, Desai VJ, Grossberg R, Nair SR, Pujar B, Riska PF, Root HB, Toro J, <strong>Torres JA</strong>, Pirofski LA, Zingman BS. Anorectal Testing for Monkeypox Virus Infection in Men who have Sex with Men with and without Proctitis. Clin Infect Dis. 2022 Oct 13:ciac825. doi: 10.1093/cid/ciac825. Epub ahead of print. PMID: 36227656 <strong>(2022)</strong></span></p>
<p>Julian A. Torres lsasiga, MD, is an attending physician at Montefiore Einstein and Associate Professor, Infectious Diseases at our Albert Einstein College of Medicine. Dr. Torres’s clinical focus centers on general infectious disease care, HIV prevention and care, sexually transmitted infections and medical education.</p><p>After earning his Doctor of Medicine at the Universidad del Valle/Hospital Universitario del Valle in Cali, Colombia in 2006, Dr. Torres became a research assistant at the International Center for Medical Research and Training (CIDEIM) in Cali, Colombia, from 2007 to 2009. He then moved to the United States to continue his medical training, completing his internal medicine residency at Jacobi Medical Center in 2012 and an infectious disease fellowship at New York University in 2014.</p><p>Building on his clinical focus, Dr. Torres’s research is focused on HIV prevention and pre-exposure prophylaxis (PrEP). He has been co-investigator, principal investigator and sub-investigator on several research projects and he has shared his work through many national and international invited presentations and poster presentations. Dr. Torres is a reviewer for <em>Clinical Infectious Disease, Open Forum Infectious Disease</em> and the <em>International Journal of STD & AIDS</em>. His work has been published in numerous peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Torres is board certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine. He is a member of the Infectious Disease Society of America. In 2023, he received the Excellence in Teaching Award from the Division of Infectious Disease at Montefiore Einstein. The same year, Dr. Torres received the Teaching Star-Teaching Commendation Letter for the 2022-2023 Academic Year from Montefiore Einstein.</p>